09:00 – 09:30
Registration & Welcome Coffee
Informal networking and introduction to the course team
09:30 – 10:00
Opening Keynote: The Evolving Role of Incretin-Based Therapies
Speaker: Dr in Obesity Medicine
- Overview of GLP-1 and GIP biology
- Historical context and breakthrough moment in metabolic disease management
- NICE and international guideline positioning
10:00 – 11:00
Session 1: Semaglutide – Mechanism, Evidence & Clinical Use
- Mechanism of action and dose escalation
- Overview of STEP and SELECT trials
- Managing GI side effects and patient expectations
- Dosing, formulations (injectable vs oral), and practical prescribing
11:00 – 11:15
Morning Break
11:15 – 12:15
Session 2: Tirzepatide – Dual Agonist, Dual Benefit
- Mechanism of GIP/GLP-1 dual agonism
- SURPASS and SURMOUNT data highlights
- Real-world insights and differences from semaglutide
- Dose titration strategies and safety considerations
12:15 – 13:00
Panel Discussion: Choosing the Right Agent – A Case-Based Approach
Facilitated by expert panel including endocrinology, primary care, and obesity clinicians
- Real-world patient case studies
- Managing side effects, comorbidities, and patient preferences
- Open Q&A
13:00 – 14:00
Lunch Break & Networking
14:00 – 14:45
Session 3: Behavioural Science & Pharmacotherapy – Working in Tandem
- Setting realistic goals in the age of weight loss injections
- Patient motivation, shared decision-making, and adherence
- Avoiding medication-only models
14:45 – 15:30
Session 4: Navigating Guidelines, Licensing & Off-label Considerations
- NICE guidance (NG28, NG136, NG224), MHRA licensing
- Prescribing in the private sector vs NHS
- Managing risk, documentation, and patient consent
15:30 – 15:45
Afternoon Break
15:45 – 16:30
Session 5: Monitoring, Maintenance, and Long-Term Success
- Transitioning off medication
- Managing weight plateaus and psychological factors
- Metabolic monitoring and follow-up frameworks
16:30 – 17:00
Closing Session: What’s Next? Emerging Therapies & Future Research
- Brief overview of retatrutide, orforglipron, amycretin
- Upcoming trial data and practical implications
- Final Q&A and certificate distribution
CPD Accreditation:
This masterclass is eligible for 6 CPD points. Certificate of completion provided.